You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Pharmacy Articles
Popular Pharmacy Articles
Highly Recommended Pharmacy Articles
Send a link to this page to your friends and colleagues.
A long-term study published in a recent issue of the Journal of Palliative Medicine found that Eli Lilly’s non-narcotic prescription drug Cymbalta (duloxetine HCl) is as safe and well-tolerated as current routine care that uses one or more medications for the management of pain caused by diabetic nerve damage. Study findings also show that Cymbalta did not adversely affect the progression of diabetes or many of the complications associated with the illness, such as damage to the nerves, kidneys and eyes.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately half of all people with diabetes have some form of nerve damage, or neuropathy. Not all, however, will develop symptoms.
Cymbalta is approved in the United States for the treatment of major depressive disorder and the management of diabetic peripheral neuropathic pain, both in adults. It is not approved for use in pediatric patients.
For full patient information, visit the Web site at www.Cymbalta.com.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.